The ARK2N Knockout HAP1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt the ARK2N gene in the HAP1 cell line. This product offers a loss-of-function model for studying the biological functions of ARK2N, a RING-type E3 ubiquitin ligase. The polyclonal format provides a mixed population of edited cells, suitable for pooled screening and functional genomics without single-cell cloning. CRISPR/Cas9-mediated gene disruption enables efficient target ablation, facilitating investigations into ARK2N-dependent processes.
The host HAP1 cell line is a near-haploid human line derived from the KBM-7 chronic myeloid leukemia (CML) cell line. HAP1 cells are adherent and fibroblast-like and express the BCR-ABL oncogenic fusion protein. The near-haploid karyotype, with a single copy of most chromosomes, simplifies genetic manipulation and knockout analysis, as biallelic targeting is not required. This genetic simplicity makes HAP1 a powerful platform for CRISPR/Cas9-based functional studies, especially in a leukemic context.
ARK2N (Arkadia-like 2) is a RING-type E3 ubiquitin ligase that operates in the ubiquitin-proteasome system. It functions with E2 enzymes UBE2D1 and UBE2D2 to ubiquitinate substrates, targeting them for proteasomal degradation. By similarity to ARKadia (RNF111), ARK2N likely regulates TGF-beta signaling through ubiquitination of SMAD7, downstream of TGF-beta and stress signals. The full range of substrates and biological roles remains largely unknown, highlighting the need for this knockout tool.
In the HAP1 leukemia model, ARK2N knockout offers a unique opportunity to dissect the crosstalk between the ubiquitin-proteasome system and BCR-ABL-driven oncogenic signaling. ARK2N may influence critical cellular processes such as proliferation, apoptosis, or stress responses in the leukemic background. The polyclonal knockout population minimizes clonal artifacts and provides a robust system for high-throughput functional assays. This model is particularly valuable for uncovering potential therapeutic targets within the ubiquitin pathway in CML.
Researchers can utilize this model for Western blotting, RT-qPCR, ubiquitination assays, proteasome activity tests, and cell viability assays. TGF-beta pathway reporters can assess signaling changes. The cells are also applicable to drug screens targeting the ubiquitin system. For additional details, contact Ascent Research.
